Cholangiocarcinoma treatment

Current Gastroenterology Reports

Volumn 14, Issue 6, 2012, Pages 528-533

  Charbel, Halim ^a,b   Al Kawas, Firas H ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Biliary; Cholangiocarcinoma; Ercp; Klatskin tumor

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; LOMUSTINE; MITOMYCIN C; PACLITAXEL; PHOTOSENSITIZING AGENT;

ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT DRAINAGE; BILIARY TRACT SURGERY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; ENDOSCOPIC THERAPY; EXTERNAL BEAM RADIOTHERAPY; HIGH INTENSITY FOCUSED ULTRASOUND; HISTOPATHOLOGY; HUMAN; LIVER GRAFT; MAINTENANCE THERAPY; MONOTHERAPY; PHOTODYNAMIC THERAPY; STENT; SURVIVAL RATE; SURVIVAL TIME;

EID: 84870499652     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-012-0286-0     Document Type: Article

References (52)

1. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341:1368-78
2. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224:463-73. discussion 73-5
3. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234:507-17. discussion 17-9
4. Jarnagin WR, Shoup M. Surgical management of cholangiocarcinoma. Semin Liver Dis. 2004;24:189-99
5. Valverde A, Bonhomme N, Farges O, Sauvanet A, Flejou JF, Belghiti J. Resection of intrahepatic cholangiocarcinoma: a Western experience. J Hepatobiliary Pancreat Surg. 1999;6:122-7
6. Ohtsuka M, Ito H, Kimura F, et al. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg. 2002;89:1525-31
7. Nagorney DM, Kendrick ML. Hepatic resection in the treatment of hilar cholangiocarcinoma. Adv Surg. 2006;40:159-71
8. DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245:755-62
9. Nagino M, Kamiya J, Nishio H, Ebata T, Arai T, Nimura Y. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-Term follow-up. Ann Surg. 2006;243:364-72
10. Heimbach JK, Gores GJ, Haddock MG, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis. 2004;24:201-7
11. Sudan D, DeRoover A, Chinnakotla S, et al. Radiochemotherapy and transplantation allow long-Term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant. 2002;2:774-9
12. Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of Neoadjuvant Chemoradiation, Followed by Liver Transplantation, for Perihilar Cholangiocarcinoma at 12 US Centers. Gastroenterology. Significant survival benefit is demonstrated with liver transplant after neoadjuvant chemoradiation in perihilar CCA
13. Ortner MA, Dorta G. Technology insight: photodynamic therapy for cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 2006;3:459-67
14. Abels C. Targeting of the vascular system of solid tumours by photodynamic therapy (PDT). Photochem Photobiol Sci. 2004;3:765-71
15. Korbelik M, Dougherty GJ. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res. 1999;59:1941-6
16. Dougherty TJ, Mang TS. Characterization of intra-Tumoral porphyrin following injection of hematoporphyrin derivative or its purified component. Photochem Photobiol. 1987;46:67-70
17. McCaughan Jr JS, Mertens BF, Cho C, Barabash RD, Payton HW. Photodynamic therapy to treat tumors of the extrahepatic biliary ducts. A case report. Arch Surg. 1991;126:111-3
18. Rumalla A, Baron TH, Wang KK, Gores GJ, Stadheim LM, de Groen PC. Endoscopic application of photodynamic therapy for cholangiocarcinoma. Gastrointest Endosc. 2001;53:500-4
19. Dumoulin FL, Gerhardt T, Fuchs S, et al. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc. 2003;57:860-7
20. Ortner ME, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology. 2003;125:1355-63
21. Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol. 2005;100:2426-30
22. Witzigmann H, Berr F, Ringel U, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg. 2006;244:230-9
23. Zoepf T. Photodynamic therapy of cholangiocarcinoma. HPB (Oxford). 2008;10:161-3
24. Berr F. Photodynamic therapy for cholangiocarcinoma. Semin Liver Dis. 2004;24:177-87
25. Nanashima A, Yamaguchi H, Shibasaki S, et al. Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study. J Gastroenterol. 2004;39:1095-101
26. Wiedmann M, Caca K, Berr F, et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer. 2003;97:2783-90
27. Smith AC, Dowsett JF, Russell RC, Hatfield AR, Cotton PB. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bile duct obstruction. Lancet. 1994;344:1655-60
28. Chamberlain RS, Blumgart LH. Hilar cholangiocarcinoma: a review and commentary. Ann Surg Oncol. 2000;7:55-66
29. Raijman I. Biliary and pancreatic stents. Gastrointest Endosc Clin N Am. 2003;13:561-92. vii-viii
30. Dowsett JF, Vaira D, Hatfield AR, et al. Endoscopic biliary therapy using the combined percutaneous and endoscopic technique. Gastroenterology. 1989;96:1180-6
31. Deviere J, Baize M, de Toeuf J, Cremer M. Long-Term follow-up of patients with hilar malignant stricture treated by endoscopic internal biliary drainage. Gastrointest Endosc. 1988;34:95-101
32. De Palma GD, Galloro G, Siciliano S, Iovino P, Catanzano C. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc. 2001;53:547-53
33. Hintze RE, Abou-Rebyeh H, Adler A, Veltzke-SchliekerW, Felix R, Wiedenmann B. Magnetic resonance cholangiopancreatographyguided unilateral endoscopic stent placement for Klatskin tumors. Gastrointest Endosc. 2001;53:40-6
34. Prat F, Chapat O, Ducot B, et al. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc. 1998;47:1-7
35. Kaassis M, Boyer J, Dumas R, et al. Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest Endosc. 2003;57:178-82
36. Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet. 1992;340:1488-92
37. Chang WH, Kortan P, Haber GB. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc. 1998;47:354-62
38. Peters RA, Williams SG, Lombard M, Karani J, Westaby D. The management of high-grade hilar strictures by endoscopic insertion of self-expanding metal endoprostheses. Endoscopy. 1997;29:10-6
39. Steel AW, Postgate AJ, Khorsandi S, et al. Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction. Gastrointest Endosc. 2011;73: 149-53. This study introduced radiofrequency ablation as a new technique for palliation of malignant biliary strictures
40. Gerhards MF, van Gulik TM, Gonzalez Gonzalez D, Rauws EA, Gouma DJ. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg. 2003;27:173-9
41. Bruha R, Petrtyl J, Kubecova M, et al. Intraluminal brachytherapy and selfexpandable stents in nonresectable biliary malignancies-The question of long-Term palliation. Hepatogastroenterology. 2001;48:631-7
42. Montemaggi P, Costamagna G, Dobelbower RR, et al. Intraluminal brachytherapy in the treatment of pancreas and bile duct carcinoma. Int J Radiat Oncol Biol Phys. 1995;32:437-43
43. Todoroki T. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology. 2000;47:644-9
44. Hejna M, Pruckmayer M, Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer. 1998;34:977-86
45. Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology. 2001;48:783-9
46. Ducreux M, Rougier P, Fandi A, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol. 1998;9:653-6
47. Lee MA, Woo IS, Kang JH, Hong YS, Lee KS. Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma. J Cancer Res Clin Oncol. 2004;130:346-50
48. Raderer M, Hejna MH, Valencak JB, et al. Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology. 1999;56:177-80
49. Kiba T, Nishimura T, Matsumoto S, et al. Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature. Oncology. 2006;70:358-65
50. Scheithauer W. Review of gemcitabine in biliary tract carcinoma. Semin Oncol. 2002;29:40-5
51. Prat F, Lafon C, Margonari J, et al. A high-intensity US probe designed for intraductal tumor destruction: experimental results. Gastrointest Endosc. 1999;50:388-92
52. Wiedmann M, Feisthammel J, Bluthner T, et al. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs. 2006;17:783-95.